Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer

International Journal of Cancer

Volumn 86, Issue 3, 2000, Pages 122-126

  Li, Chenggang ^e   Guo, Baoqiang ^e   Wilson, Phillip B ^a   Stewart, Alan ^b   Byrne, Ged ^c   Bundred, Nigel ^c   Kumar, Shant ^b,d  

^a ST MARY S HOSPITAL   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c WITHINGTON HOSPITAL   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ENDOGLIN; TRANSFORMING GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA1; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER GROWTH; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD; BREAST TUMOR; CANCER STAGING; CASE CONTROL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOLOGY; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY;

ADULT; ANTIGENS, CD; BREAST NEOPLASMS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; RECEPTORS, CELL SURFACE; TRANSFORMING GROWTH FACTOR BETA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0034688954     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0215(20000320)89:2<122::aid-ijc4>3.0.co;2-m     Document Type: Article

References (32)

1. AUVINEN, P., LIPPONEN, P., JOHANSSON, R. and SYRJÄNEN, K., Prognostic significance of TGF-β1 and TGF-β2 expressions in female breast cancer. Anticancer Res., 15, 2627-2631 (1995).
2. BODEY, B., BODEY JR, B., SIEGEL, S.E. and KAISER, H.E., Upregulation of endoglin (CD105) expression during childhood brain tumour-related angiogenesis. Anticancer Res. 18, 1485-1500 (1998).
3. BURROWS, F.J., DERBYSHIRE, E.J., TAZZARI, P.L., AMLOT, P., GAZDAR, A.F., KING, S.W., LETARTE, M., VITELLA, E.S. and THORPE, P.E., Up-regulation of endoglin on vascular endothelial cells in human solid tumours: implications for diagniosis and therapy. Clin. Cancer Res., 1, 1623-1634(1995).
4. DIRIX, L.Y., VERMEULEN, P.B., PAWINSKI, A., PROVE, A., BENOY, I., DE POOTER, C., MARTIN, M. and VAN OSTEROM, A.T., Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Brit. J. Cancer, 76, 238-243 (1997).
5. EPPENBERGER, U. and 12 OTHERS, Markers of tumour angiogenesis and proteolysis independently define high-and low-risk subsets of node-negative breast cancer patients. J. clin. Oncol., 16, 3129-3196 (1998).
6. FOLKMAN, J., Angiogenesis and breast cancer. J. clin. Oncol., 12, 441-443 (1994).
7. FREY, R.S. and MULDER, K.M., Involvement of extracellular signal-regulated kinase 2 and stress-activated protein kinase/Jun N-terminal kinase activation by transforming growth factor β in the negative growth control of breast cancer cells. Cancer Res., 57, 628-633 (1997).
8. GRAINGER, D.J., HEATHCOTE, K., CHIANO, M., SNIEDER, H., KEMP, P.R., METCALFE, J.C., CARTER, N.D. and SPECTOR, T.D., Genetic control of the circulating concentration of transforming growth factor type β1. Hum. Mol. Genet., 8, 93-97 (1999).
9. GRAINGER, D.J., MOSEDALE, D.E., METCALFE, J.C., WEISSBERG, P.L. and KEMP, P.R., Active and acid-activatable TGF-β in human sera, platelets and plasma. Clin. chim. Acta, 235, 11-31 (1995).
10. HATA, A., SHI, Y. and MASSAGUÉ, J., TGFβ signaling and cancer: structural and functional consequences of mutations in Smads. Mol. Med. Today, 4, 257-262 (1998).
11. KNABBE, C., KOPP, A., HILGERS, W., LANG, D., MULLER, V., ZUGMAIER, G. and JONAT, W., Regulation and role of TGFβ production in breast cancer. Ann. N.Y. Acad. Sci., 784, 263-276 (1996).
12. KONG, F.M., ANSCHER, M.S., MURASE, T., ABBOTT, B.D., IGLEHART, J.D. and JIRTLE, R.L., Elevated plasma transforming growth factor-β1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann. Surg., 222, 155-162 (1995).
13. KRUPINSKI, J., KALUZA, J., KUMAR, P., KUMAR, S. and WANG, J.M., Role of angiogenesis in patients with cerebral ischemic stroke. Stroke, 25, 1794-1798 (1994).
14. KUMAR, S., GHELLAL, A., LI, C.G., BYRNE, G., HABONI, N., WANG, J.M. and BUNDRED, N., Breast carcinoma: vascular density determined using CD105 antibody correlates with tumour prognosis. Cancer Res., 59, 856-861 (1999).
15. KUMAR, S., WANG, J.M. and BERNABEU, C., CD105 and angiogenesis. J. Pathol, 178, 363-366 (1996).
16. LANDRISCINA, M., CASSANO, A., RATTO, C., LONGO, R., IPPOLITI, M., PALAZZOTTI, B., CRUCITTI, F. and BARONE, C., Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer. Brit. J. Cancer, 78, 765-770 (1998).
17. LASTRES, P., LETAMENDIA, A., ZHANG, H., RIUS, C., ALMENDRO, N., RAAB, U., LOPEZ, L.A., LANGA, C., FABRA, A., LETARTE, M. and BERNABEU, C., Endoglin modulates cellular responses to TGF-β1. J. Cell Biol., 133, 1109-1121 (1996).
18. LI, C.G., WILSON, P.B., BERNABEU, C., RAAB, U., WANG, J.M. and KUMAR, S., Immunodetection and characterisation of soluble CD105-TGFβ complexes. J. immunol. Methods, 218, 85-93 (1998).
19. LI, C.G., WILSON, P.B., LEVINE, E., BARBER, J. and KUMAR, S., TGFβ1 levels in pre-treatment plasma identify patients at risk of developing breast fibrosis post-radiotherapy. Int. J. Cancer, 84, 155-159 (1999).
20. LI, D.Y., SORENSEN, L.K., BROOK, B.S., URNESS, L.D., DAVIS, E.C., TAYLOR, D.G., BOAK, B.B. and WENDEL, D.P., Defective angiogenesis in mice lacking endoglin. Science, 284, 1534-1537 (1999).
21. LI, V.W., FOLKERTH, R.D., WATANABE, H., YU, C., RUPNICK, M., BARNES, P., SCOTT, R.M., BLACK, P.M., SALLAN, S.E. and FOLKMAN, J., Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours. Lancet, 344, 82-86 (1994).
22. MATSUNO, F., HARUTA, Y., KONDO, M., TSAI, H., BARCOS, M. and SEON, B.K., Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin. Cancer Res., 5, 371-382 (1999).
23. MEYER, G.E., YU, E., SIEGAL, J.A., PETTEWAY, J.C., BLUMENSTEIN, B.A. and BRAWER, M.K., Serum basic fibroblast growth factor in men with and without prostate carcinoma. Cancer, 76, 2304-2311 (1995).
24. MIYAZONO, K., ICHIJO, H. and HELDIN, C.H., Transforming growth factor-β: latent forms, binding proteins and receptors. Growth Factors, 8, 11-22 (1993).
25. PEPPER, M.S., Transforming growth factor-β: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev., 8, 21-43 (1997).
26. PICHUANTES, S., VERA, S., BOURDEAU, A., PECE, N., KUMAR, S., WAYNER, E.A. and LETARTE, M., Mapping epitopes to distinct regions of the extra-cellular domain of endoglin using bacterially expressed recombinant fragments. Tissue Antigens, 50, 265-276 (1997).
27. WALKER, R.A., DEARING, S.J. and GALLACHER, B., Relationship of transforming growth factor β1 to extracellular matrix and stromal infiltrates in invasive breast carcinoma. Brit. J. Cancer, 69, 1160-1165 (1994).
28. WANG, J.M., KUMAR, S., PYE, D., HABOUBI, N. and AL-NAKIB, L., Breast carcinoma: comparative study of tumor vasculature using two endothelial cell markers. J. nat. Cancer Inst., 86, 386-388 (1994).
29. WANG, J.M., KUMAR, S., PYE, D., VAN AGTHOREN, A., KRUPINSKI, J. and HUNTER, R.D., A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int. J. Cancer, 54, 363-370 (1993).
30. WANG, J.M., KUMAR, S., VAN AGTHOREN, A., KUMAR, P., PYE, D. and HUNTER, R.D., Irradiation induces up-regulation of E9 protein (CD105) in human vascular endothelial cells. Int. J. Cancer, 62, 791-796 (1995).
31. WEIDNER, N., Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow. J. Pathol., 184, 119-122 (1998).
32. YAMAMOTO, S., KONISHI, I., MANDAI, M., KURODA, H., KOMATSU, T., NANBU, K., SAKAHARA H. and MORI, T., Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival and analysis of serum VEGF levels. Brit. J. Cancer, 76, 1221-1227 (1997).